Stocktoria
Outlook Therapeutics, Inc. OTLK
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2016-06-13
Outlook Therapeutics, Inc. statistics & valuation
Market cap$273.9M
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 4.0% | — | — | — | — |
| Operating margin | -4744.3% | — | — | — | — |
| Net margin | -4416.2% | — | — | — | — |
| Return on assets | -335.9% | -261.5% | -182.6% | -231.5% | -233.1% |
| Return on equity | 193.9% | 103.1% | 408.5% | -756.0% | -1153.9% |
| Current ratio | 0.38 | 0.64 | 0.66 | 1.39 | 3.19 |
Source: SEC EDGAR filings · CIK 0001649989 · as of 2025-09-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.